Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Nathalie Charland, Aurélien Lorin, Matthew P. Cheng, Donald C. Vinh, Philippe Boutet, Robbert Most, François Roman, Maria Angeles Ceregido, Nathalie Landry, Marc-André D’Aoust and Brian J. Ward ()
Additional contact information
Philipe Gobeil: Medicago Inc.
Stéphane Pillet: Medicago Inc.
Iohann Boulay: Medicago Inc.
Nathalie Charland: Medicago Inc.
Aurélien Lorin: Medicago Inc.
Matthew P. Cheng: The Research Institute of the McGill University Health Centre
Donald C. Vinh: The Research Institute of the McGill University Health Centre
Philippe Boutet: GlaxoSmithKline (Vaccines)
Robbert Most: GlaxoSmithKline (Vaccines)
François Roman: GlaxoSmithKline (Vaccines)
Maria Angeles Ceregido: GlaxoSmithKline (Vaccines)
Nathalie Landry: Medicago Inc.
Marc-André D’Aoust: Medicago Inc.
Brian J. Ward: Medicago Inc.

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract As the SARS-CoV-2 pandemic evolves, vaccine evaluation needs to include consideration of both durability and cross-reactivity. This report expands on previously reported results from a Phase 1 trial of an AS03-adjuvanted, plant-based coronavirus-like particle (CoVLP) displaying the spike (S) glycoprotein of the ancestral SARS-CoV-2 virus in healthy adults (NCT04450004). Humoral and cellular responses against the ancestral strain were evaluated 6 months post-second dose (D201) as secondary outcomes. Independent of dose, all vaccinated individuals retain binding antibodies, and ~95% retain neutralizing antibodies (NAb). Interferon gamma and interleukin-4 responses remain detectable in ~94% and ~92% of vaccinees respectively. In post-hoc analyses, variant-specific (Alpha, Beta, Delta, Gamma and Omicron) NAb were assessed at D42 and D201. Using a live virus neutralization assay, broad cross-reactivity is detectable against all variants at D42. At D201, cross-reactive antibodies are detectable in almost all participants against Alpha, Gamma and Delta variants (94%) and the Beta variant (83%) and in a smaller proportion against Omicron (44%). Results are similar with the pseudovirion assay. These data suggest that two doses of 3.75 µg CoVLP+AS03 elicit a durable and cross-reactive response that persists for at least 6 months post-vaccination.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-34728-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34728-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-34728-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().